Events

Cluster 6 - Commission Info days on 2023 call topics
DEC
Tue
13
DEC
Wed
14

This was 2 years ago

Location

Virtually

Programmes
Agro-Food, Environment

The Horizon Europe Cluster 6 Information Days are going to be held virtually on 13 and 14 December 2022.

At the Info Days the topics of the Cluster 6 2023 call topics will be presented. (Prospective) applicants will get the opportunity to familiarise with the new topics under the 2023 work programme and to raise questions. 

More information and registration on the Commission website.

The Commission Info Days will be followed by a Brokerage event on 19 December 2022, organised by the CARE4BIO project. This will complement the Info Days with an offer of networking and matchmaking opportunities to prospective applicants to support the building of proposals’ consortia.

 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.